190 related articles for article (PubMed ID: 30894682)
1. ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma.
Yamaguchi T; Hayashi M; Ida L; Yamamoto M; Lu C; Kajino T; Cheng J; Nakatochi M; Isomura H; Yamazaki M; Suzuki M; Fujimoto T; Takahashi T
Oncogene; 2019 Jun; 38(26):5142-5157. PubMed ID: 30894682
[TBL] [Abstract][Full Text] [Related]
2. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1.
Yamaguchi T; Lu C; Ida L; Yanagisawa K; Usukura J; Cheng J; Hotta N; Shimada Y; Isomura H; Suzuki M; Fujimoto T; Takahashi T
Nat Commun; 2016 Jan; 7():10060. PubMed ID: 26725982
[TBL] [Abstract][Full Text] [Related]
3. Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
Ida L; Yamaguchi T; Yanagisawa K; Kajino T; Shimada Y; Suzuki M; Takahashi T
Cancer Sci; 2016 Feb; 107(2):155-61. PubMed ID: 26661061
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma.
Khaledian B; Taguchi A; Shin-Ya K; Kondo-Ida L; Kagaya N; Suzuki M; Kajino T; Yamaguchi T; Shimada Y; Takahashi T
Cancer Sci; 2021 Mar; 112(3):1225-1234. PubMed ID: 33370472
[TBL] [Abstract][Full Text] [Related]
5. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.
Yamaguchi T; Yanagisawa K; Sugiyama R; Hosono Y; Shimada Y; Arima C; Kato S; Tomida S; Suzuki M; Osada H; Takahashi T
Cancer Cell; 2012 Mar; 21(3):348-61. PubMed ID: 22439932
[TBL] [Abstract][Full Text] [Related]
6. Functional and clinical significance of ROR1 in lung adenocarcinoma.
Schiavone G; Epistolio S; Martin V; Molinari F; Barizzi J; Mazzucchelli L; Frattini M; Wannesson L
BMC Cancer; 2020 Nov; 20(1):1085. PubMed ID: 33172431
[TBL] [Abstract][Full Text] [Related]
7. Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1α regulator.
Isomura H; Taguchi A; Kajino T; Asai N; Nakatochi M; Kato S; Suzuki K; Yanagisawa K; Suzuki M; Fujishita T; Yamaguchi T; Takahashi M; Takahashi T
Cancer Sci; 2021 Apr; 112(4):1614-1623. PubMed ID: 33506575
[TBL] [Abstract][Full Text] [Related]
8. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.
Liu Y; Yang H; Chen T; Luo Y; Xu Z; Li Y; Yang J
PLoS One; 2015; 10(5):e0127092. PubMed ID: 25978653
[TBL] [Abstract][Full Text] [Related]
9. Cavin3 interacts with cavin1 and caveolin1 to increase surface dynamics of caveolae.
Mohan J; Morén B; Larsson E; Holst MR; Lundmark R
J Cell Sci; 2015 Mar; 128(5):979-91. PubMed ID: 25588833
[TBL] [Abstract][Full Text] [Related]
10. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis.
Gentile A; Lazzari L; Benvenuti S; Trusolino L; Comoglio PM
Cancer Res; 2011 Apr; 71(8):3132-41. PubMed ID: 21487037
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA ROR1-AS1 enhances lung adenocarcinoma metastasis and induces epithelial-mesenchymal transition by sponging miR-375.
Xu N; Qiao L; Yin L; Li H
J BUON; 2019; 24(6):2273-2279. PubMed ID: 31983094
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target.
Heliste J; Jokilammi A; Paatero I; Chakroborty D; Stark C; Savunen T; Laaksonen M; Elenius K
BMC Cardiovasc Disord; 2018 Oct; 18(1):196. PubMed ID: 30342492
[TBL] [Abstract][Full Text] [Related]
13. Nuclear localization of orphan receptor protein kinase (Ror1) is mediated through the juxtamembrane domain.
Tseng HC; Lyu PC; Lin WC
BMC Cell Biol; 2010 Jun; 11():48. PubMed ID: 20587074
[TBL] [Abstract][Full Text] [Related]
14. Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer.
Liu X; Pu W; He H; Fan X; Zheng Y; Zhou JK; Ma R; He J; Zheng Y; Wu K; Zhao Y; Yang SY; Wang C; Wei YQ; Wei XW; Peng Y
Cancer Lett; 2019 Aug; 458():76-85. PubMed ID: 31125641
[TBL] [Abstract][Full Text] [Related]
15. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.
Karachaliou N; Gimenez-Capitan A; Drozdowskyj A; Viteri S; Moran T; Carcereny E; Massuti B; Vergnenegre A; de Marinis F; Molina MA; Teixido C; Rosell R
Transl Lung Cancer Res; 2014 Jun; 3(3):122-30. PubMed ID: 25806291
[TBL] [Abstract][Full Text] [Related]
16. The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.
Gentile A; Lazzari L; Benvenuti S; Trusolino L; Comoglio PM
Int J Cancer; 2014 Nov; 135(10):2305-16. PubMed ID: 24706440
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of receptor tyrosine kinase-like orphan receptor 1 in preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion by PI3K/AKT/mTOR pathway accommodation.
Chen J; Yue C; Xu J; Zhan Y; Zhao H; Li Y; Ye Y
Placenta; 2019 Jul; 82():17-24. PubMed ID: 31174622
[TBL] [Abstract][Full Text] [Related]
18. ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.
Mao Y; Xu L; Wang J; Zhang L; Hou N; Xu J; Wang L; Yang S; Chen Y; Xiong L; Zhu J; Fan W; Xu J
Biofactors; 2019 May; 45(3):416-426. PubMed ID: 30801854
[TBL] [Abstract][Full Text] [Related]
19. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
20. ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.
Zheng YZ; Ma R; Zhou JK; Guo CL; Wang YS; Li ZG; Liu LX; Peng Y
Sci Rep; 2016 Nov; 6():36447. PubMed ID: 27830754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
